We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfun... Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems. Show more
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors...
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report...
false 0001625101 0001625101 2024-03-08 2024-03-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced receipt of U.S. Food and Drug...
false 0001625101 0001625101 2024-02-14 2024-02-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field (nsPFA) technology for the treatment of atrial...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.65 | -17.4973488865 | 9.43 | 9.675 | 7.93 | 121087 | 8.68700525 | CS |
4 | -2.57 | -24.8309178744 | 10.35 | 11.6398 | 7.93 | 146972 | 9.69216381 | CS |
12 | -2.22 | -22.2 | 10 | 11.6398 | 7.77 | 171965 | 9.15463896 | CS |
26 | 3.64 | 87.922705314 | 4.14 | 13.62 | 3.78 | 217867 | 8.83379885 | CS |
52 | 4.9278 | 172.771895379 | 2.8522 | 13.62 | 2.36 | 195006 | 7.6968875 | CS |
156 | -14.97 | -65.8021978022 | 22.75 | 29.16 | 1.18 | 150655 | 7.43293513 | CS |
260 | -9.82 | -55.7954545455 | 17.6 | 45.82 | 1.18 | 125711 | 9.8458066 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions